Biomarin surges on acquisition move to bolster rare disease pipeline

27 days ago

Tim Savec

"Yes, this stock is up in a big way. It's up 17%, biggest jump since November 16. Biomarin Pharm Pharmaceutical BMRN. They agreed to buy Amicus Therapeutics, which is a biotech company that will help the company expand its treatments for rare diseases. So, they specialize in rare disease. And that stock, Amicus, is also up in a pretty big way with some double digit gain. Deal news in the pharma industry is clearly driving the move."

Biomarin (BMRN) experienced a sharp 17% jump following news of its acquisition of Amicus Therapeutics. The move is seen as a strategic play to expand its rare disease treatment portfolio, with the market responding positively to the deal news.

Related Stocks